Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQSTNASDAQ:ARCTNASDAQ:JMACNASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$3.42+3.3%$2.76$2.12▼$5.80$339.70M1.941.55 million shs1.22 million shsARCTArcturus Therapeutics$12.38-2.1%$11.76$8.04▼$30.39$335.76M2.3438,553 shs433,067 shsJMACMaxpro Capital Acquisition$6.07-12.2%$6.08$7.50▼$19.22$81.55M0.0174,040 shs3,939 shsSNDLSNDL$1.29-4.4%$1.34$1.24▼$2.40$338.98M3.451.98 million shs2.06 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%-3.93%+43.70%+20.42%+21.71%ARCTArcturus Therapeutics0.00%-3.21%+6.36%-12.07%-60.14%JMACMaxpro Capital Acquisition-10.90%-6.57%+23.69%-21.03%+2,527.87%SNDLSNDL0.00%-2.27%+0.78%-14.57%-37.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQSTAquestive Therapeutics1.6842 of 5 stars3.51.00.00.04.00.00.0ARCTArcturus Therapeutics3.2126 of 5 stars4.60.00.00.03.52.50.6JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASNDLSNDL3.5723 of 5 stars3.55.00.00.02.20.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.14196.57% UpsideARCTArcturus Therapeutics 3.11Buy$53.50332.15% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ASNDLSNDL 3.00Buy$3.63181.01% UpsideCurrent Analyst Ratings BreakdownLatest JMAC, SNDL, AQST, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/15/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/13/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$68.00 ➝ $66.004/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025SNDLSNDLATB CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price Target$3.50 ➝ $4.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$54.23M6.26N/AN/A($1.59) per share-2.15ARCTArcturus Therapeutics$131.27M2.56N/AN/A$10.42 per share1.19JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ASNDLSNDL$927.61M0.37N/AN/A$3.47 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$7.87M-$0.59N/AN/AN/A-59.75%N/A-33.96%8/5/2025 (Estimated)ARCTArcturus Therapeutics-$29.73M-$2.53N/AN/AN/A-36.39%-22.39%-14.81%8/4/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ASNDLSNDL-$127.91M-$0.29N/AN/AN/A-12.11%-8.27%-6.96%7/30/2025 (Estimated)Latest JMAC, SNDL, AQST, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AQSTAquestive Therapeutics-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AARCTArcturus Therapeutics$0.715.78%N/AN/A N/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A6.375.91ARCTArcturus TherapeuticsN/A4.764.76JMACMaxpro Capital AcquisitionN/AN/AN/ASNDLSNDL0.105.614.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%ARCTArcturus Therapeutics94.54%JMACMaxpro Capital Acquisition73.18%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics8.35%ARCTArcturus Therapeutics15.30%JMACMaxpro Capital Acquisition19.27%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.33 million84.02 millionOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableSNDLSNDL580262.78 millionN/AOptionableJMAC, SNDL, AQST, and ARCT HeadlinesRecent News About These CompaniesHYTN Receives Initial International Purchase Order for GMP Vape CartridgesJune 11, 2025 | finance.yahoo.comMarijuana Stocks To Watch With Strong Market PotentialJune 6, 2025 | marijuanastocks.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 612,495 Shares of SNDL Inc. (NASDAQ:SNDL)May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in SNDL Inc. (NASDAQ:SNDL)May 21, 2025 | marketbeat.com1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court OrderMay 20, 2025 | finance.yahoo.comCanadian Securities Exchange Reports April 2025 Performance FiguresMay 15, 2025 | finance.yahoo.comBNP Paribas Financial Markets Makes New $7.36 Million Investment in SNDL Inc. (NASDAQ:SNDL)May 15, 2025 | marketbeat.comSA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLIMay 5, 2025 | msn.comSNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has IncreasedMay 5, 2025 | seekingalpha.comSNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call TranscriptMay 3, 2025 | insidermonkey.comSNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2025 | finance.yahoo.com3 Marijuana Stocks For The Long Term InvestingMay 2, 2025 | marijuanastocks.comSNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market ReviewMay 2, 2025 | uk.finance.yahoo.comThese Cannabis Companies Are Repurchasing SharesMay 2, 2025 | newcannabisventures.comSNDL Inc. (SNDL) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comSNDL 1Q Loss WidensMay 2, 2025 | marketwatch.comSNDL Inc. Earnings Call Highlights Growth and ChallengesMay 1, 2025 | tipranks.comSNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue EstimatesMay 1, 2025 | zacks.comSNDL Reports Record Q1 2025 Results and Strategic InitiativesMay 1, 2025 | tipranks.comSNDL Reports First Quarter 2025 Financial and Operational ResultsMay 1, 2025 | prnewswire.comSNDL Launches Rise Rewards Loyalty ProgramApril 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJMAC, SNDL, AQST, and ARCT Company DescriptionsAquestive Therapeutics NASDAQ:AQST$3.42 +0.11 (+3.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.42 0.00 (0.00%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Arcturus Therapeutics NASDAQ:ARCT$12.38 -0.26 (-2.06%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$12.24 -0.15 (-1.17%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Maxpro Capital Acquisition NASDAQ:JMAC$6.07 -0.85 (-12.24%) As of 06/13/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.SNDL NASDAQ:SNDL$1.29 -0.06 (-4.44%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.78%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
